Candriam Luxembourg S.C.A. reduced its stake in shares of CryoLife, Inc. (NYSE:CRY) by 20.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,000 shares of the medical equipment provider’s stock after selling 15,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in CryoLife were worth $1,197,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in CRY. Elk Creek Partners LLC raised its position in CryoLife by 70.8% in the first quarter. Elk Creek Partners LLC now owns 496,917 shares of the medical equipment provider’s stock worth $8,274,000 after buying an additional 205,971 shares in the last quarter. Dialectic Capital Management LP acquired a new position in CryoLife during the first quarter worth about $2,238,000. Dimensional Fund Advisors LP raised its position in CryoLife by 5.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,849,248 shares of the medical equipment provider’s stock worth $30,790,000 after buying an additional 100,125 shares in the last quarter. Royce & Associates LP raised its position in CryoLife by 32.5% in the first quarter. Royce & Associates LP now owns 395,700 shares of the medical equipment provider’s stock worth $6,588,000 after buying an additional 97,000 shares in the last quarter. Finally, Thomson Horstmann & Bryant Inc. acquired a new position in CryoLife during the second quarter worth about $1,873,000. 68.13% of the stock is owned by hedge funds and other institutional investors.

CryoLife, Inc. (NYSE:CRY) opened at 18.40 on Friday. CryoLife, Inc. has a 52-week low of $14.03 and a 52-week high of $20.30. The firm’s 50-day moving average is $19.30 and its 200-day moving average is $17.96. The stock has a market capitalization of $615.41 million, a price-to-earnings ratio of 55.76 and a beta of 0.97.

CryoLife (NYSE:CRY) last released its quarterly earnings results on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business had revenue of $47.80 million during the quarter, compared to analysts’ expectations of $47.02 million. During the same quarter in the prior year, the business earned $0.13 earnings per share. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. Analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/cryolife-inc-cry-shares-sold-by-candriam-luxembourg-s-c-a/1480840.html.

CRY has been the subject of a number of recent research reports. Zacks Investment Research raised shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Thursday, June 8th. Northland Securities reissued a “buy” rating and set a $23.50 price target on shares of CryoLife in a research report on Friday, April 28th. Finally, BidaskClub lowered shares of CryoLife from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. CryoLife has a consensus rating of “Hold” and an average target price of $22.00.

In other news, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction that occurred on Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total transaction of $191,540.00. Following the completion of the sale, the vice president now owns 112,282 shares in the company, valued at $2,245,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.00% of the stock is owned by corporate insiders.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.